Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis

被引:221
作者
De Stefano, Nicola [1 ]
Stromillo, Maria Laura [1 ]
Giorgio, Antonio [1 ]
Bartolozzi, Maria Letizia [2 ]
Battaglini, Marco [1 ]
Baldini, Mariella [2 ]
Portaccio, Emilio [3 ]
Amato, Maria Pia [3 ]
Sormani, Maria Pia [4 ]
机构
[1] Univ Siena, Dept Med Surg & Neurosci, I-53100 Siena, Italy
[2] Hosp Empoli, Neurol Unit, Empoli, Italy
[3] Univ Florence, Dept Neurol, Florence, Italy
[4] Univ Genoa, Dept Hlth Sci DISSAL, Genoa, Italy
关键词
APPEARING WHITE-MATTER; CEREBRAL ATROPHY; DISABILITY PROGRESSION; CLINICAL-RELEVANCE; MRI; DISEASE; NATALIZUMAB; LESIONS; 5-YEAR; TRIAL;
D O I
10.1136/jnnp-2014-309903
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective To assess whether it is feasible to establish specific cut-off values able to discriminate 'physiological' or 'pathological' brain volume rates in patients with multiple sclerosis (MS). Methods The study was based on the analysis of longitudinal MRI data sets of patients with MS (n=206, 87% relapsing-remitting, 7% secondary progressive and 6% primary progressive) and healthy controls (HC; n=35). Brain atrophy rates were computed over a mean follow-up of 7.5 years (range 1-12) for patients with MS and 6.3 years (range 1-12.5) for HC with the SIENA software and expressed as annualised per cent brain volume change (PBVC/y). A weighted (on the follow-up length) receiver operating characteristic analysis and the area under the curve (AUC) were used for statistics. Results The weighted PBVC/y was -0.51 +/- 0.27% in patients with MS and -0.27 +/- 0.15% in HC (p<0.0001). There was a significant age-related difference in PBVC/y between HC older and younger than 35 years of age (p=0.02), but not in patients with MS (p=0.8). The cutoff of PBVC/y, as measured by SIENA that could maximise the accuracy in discriminating patients with MS from HC, was -0.37%, with 67% sensitivity and 80% specificity. According to the observed distribution, values of PBVC/y as measured by SIENA that could define a pathological range were above -0.52% with 95% specificity, above -0.46% with 90% specificity and above -0.40% with 80% specificity. Conclusions Our evidence-based criteria provide values able to discriminate the presence or absence of 'pathological' brain volume loss in MS with high specificity. Such results could be of great value in a clinical setting, particularly in assessing treatment efficacy in MS.
引用
收藏
页码:93 / 99
页数:7
相关论文
共 39 条
[1]  
Anderson Valerie C, 2005, Top Magn Reson Imaging, V16, P439, DOI 10.1097/01.rmr.0000245458.05654.d0
[2]   The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis [J].
Barkhof, Frederik ;
de Jong, Remko ;
Sfikas, Nikolaos ;
de Vera, Ana ;
Francis, Gordon ;
Cohen, Jeffrey .
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (13) :1704-1713
[3]   Enhanced brain extraction improves the accuracy of brain atrophy estimation [J].
Battaglini, Marco ;
Smith, Stephen M. ;
Brogi, Susanna ;
De Stefano, Nicola .
NEUROIMAGE, 2008, 40 (02) :583-589
[4]   The measurement and clinical relevance of brain atrophy in multiple sclerosis [J].
Bermel, RA ;
Bakshi, R .
LANCET NEUROLOGY, 2006, 5 (02) :158-170
[5]  
Brewer JB, 2009, BEHAV NEUROL, V21, P21, DOI [10.1155/2009/616581, 10.3233/BEN-2009-0226]
[6]   Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes [J].
De Stefano, N. ;
Giorgio, A. ;
Battaglini, M. ;
Rovaris, M. ;
Sormani, M. P. ;
Barkhof, F. ;
Korteweg, T. ;
Enzinger, C. ;
Fazekas, F. ;
Calabrese, M. ;
Dinacci, D. ;
Tedeschi, G. ;
Gass, A. ;
Montalban, X. ;
Rovira, A. ;
Thompson, A. ;
Comi, G. ;
Miller, D. H. ;
Filippi, M. .
NEUROLOGY, 2010, 74 (23) :1868-1876
[7]   Clinical Relevance of Brain Volume Measures in Multiple Sclerosis [J].
De Stefano, Nicola ;
Airas, Laura ;
Grigoriadis, Nikolaos ;
Mattle, Heinrich P. ;
O'Riordan, Jonathan ;
Oreja-Guevara, Celia ;
Sellebjerg, Finn ;
Stankoff, Bruno ;
Walczak, Agata ;
Wiendl, Heinz ;
Kieseier, Bernd C. .
CNS DRUGS, 2014, 28 (02) :147-156
[8]   Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: Results of a 5-year follow-up study [J].
Dolezal, Ondrej ;
Gabelic, Tereza ;
Horakova, Dana ;
Bergsland, Niels ;
Dwyer, Michael G. ;
Seidl, Zdenek ;
Krasensky, Jan ;
Ramasamy, Deepa P. ;
Vaneckova, Manuela ;
Havrdova, Eva ;
Zivadinov, Robert .
CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 :S42-S48
[9]   Risk factors for progression of brain atrophy in aging - Six-year follow-up of normal subjects [J].
Enzinger, C ;
Fazekas, F ;
Matthews, PM ;
Ropele, S ;
Schmidt, H ;
Smith, S ;
Schmidt, R .
NEUROLOGY, 2005, 64 (10) :1704-1711
[10]  
Evangelou N, 2000, ANN NEUROL, V47, P391, DOI 10.1002/1531-8249(200003)47:3<391::AID-ANA20>3.3.CO